Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI.

Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI. Abstract Text:

Ann Partridge,Shari Gelber,Richard D Gelber,Monica Castiglione-Gertsch,Aron Goldhirsch,Eric Winer,

BACKGROUND: The likelihood of premature menopause has not been thoroughly explored in women who remain premenopausal after adjuvant chemotherapy for breast cancer. METHODS: We used data from the International Breast Cancer Study Group (IBCSG) Trials V and VI. Trial V enrolled 1407 eligible premenopausal women randomised to no systemic therapy (No CT) or 1 cycle of perioperative CMF-based chemotherapy (PeCT) if node negative, and 6 cycles of CMF-based chemotherapy postoperatively (CMFx6) or 1 cycle perioperative CMF-based chemotherapy plus CMFx6 postoperatively (CMFx7) if node positive. From Trial VI (a 2x2 factorial designed study of 3 versus 6 initial cycles of CMF and a reintroduction of three additional courses of CMF), we included 375 women randomised to receive only six initial cycles of CMF (CMFx6). FINDINGS: We excluded women who reported no menses during 12-24 months after randomisation (N=934), hysterectomy (N=16) or bilateral oophorectomy (N=8), or missing menses data (N=57), creating a cohort of 767 women; 540 women had been randomised to PeCT or no CT, 227 randomised to CMFx6 or 7. A Cox proportional hazards model revealed that CMFx6 or 7 (HR=2.03, p<0.0001) and temporary amenorrhea (HR=1.96, p<0.0001) were associated with premature menopause. INTERPRETATION: Women who remain premenopausal after 6 or 7 cycles of CMF-based chemotherapy have a higher likelihood of going through menopause at an earlier age than women who received little or no chemotherapy. Temporary cessation of menses appears to be a marker for earlier onset of menopause. These findings may assist women and clinicians when making treatment and reproductive decisions after a diagnosis of breast cancer.

Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI. Publishing Authors By Initials

A Partridge,S Gelber,RD Gelber,M Castiglione-Gertsch,A Goldhirsch,E Winer,

For similar investigative techniques: epidemiologic methods: statistics as topic: models, statistical: proportional hazards models research abstracts see: investigative techniques: epidemiologic methods: statistics as topic: models, statistical: proportional hazards models research

PUBMED ID PMID:

MEDLINE DATE:

Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: European journal of cancer (Oxford, England : 1990

VOLUME: 43

Page Numbers: 1646-53

Journal Abbreviation: Eur. J. Cancer

ISSN: 0959-8049

DAY: 18

MONTH: 05

YEAR: 2007

Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9005373

Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI. Keywords Mesh Terms:

KEYWORDS: Proportional Hazards Models

MESH TERMS: administration & dosage

Chemical & Substance for Abstract: Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI. Information

Substance Name: Methotrexate

Registry Number: 59-05-2

Grant and Affiliation Information for Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI.

AFFILIATION: Dana-Farber Cancer Institute, Boston, MA 02115, USA. ahpartridge@partners.org

Country: England

AGENCY: United States NCI

GRANT: CA75362

ACRONYM: CA

MEDLINETA: Eur J Cancer

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI Related Publications

• A framework for interactive examination of automatic segmented tumors in a virtual environment.
• A simple approach to quality assurance in a complex ambulatory care setting.
• Advances in adjuvant endocrine therapy for postmenopausal women.
• Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI.
• Auditory cortex mapmaking: principles, projections, and plasticity.
• Branched projections in the auditory thalamocortical and corticocortical systems.
• Commoner skin diseases of the external genitalia.
• Concurrent tonotopic processing streams in auditory cortex.
• Connections of cat auditory cortex: I. Thalamocortical system.
• Connections of cat auditory cortex: II. Commissural system.
• Connections of cat auditory cortex: III. Corticocortical system.
• Cutaneous leishmaniasis; report of a case and summary of the newer concepts.
• Drospirenone/ethinyl estradiol.
• Elastic fibers in unusual dermatoses.
• Follow-up care of patients with breast cancer.
• Herpes zoster and malignancy.
• Heterogeneity of breast cancer and implications of adjuvant chemotherapy.
• How does infiltration behavior modify the composition of ambient PM2.5 in indoor spaces? An analysis of RIOPA data.
• Impact of a mixed strength and endurance exercise intervention on insulin levels in breast cancer survivors.
• Long-term psychosocial adjustment of older vs younger survivors of breast and endometrial cancer.
• Optimizing endocrine therapy for estrogen receptor-positive breast cancer: treating the right patients for the right length of time.
• Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.
• Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease.
• Preoperative therapy in invasive breast cancer: reviewing the state of the science and exploring new research directions.
• Racial Differences in Clinical Outcomes From Metastatic Breast Cancer: A Pooled Analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B.
• Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study.
• Sarcoidosis mimicking metastatic breast cancer.
• The pharmacologic management of premenstrual dysphoric disorder.
• Uterine inversion associated with bicornuate uterus.
• Vascular compliance in the cardiometabolic syndrome.